Cargando…

Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting

PURPOSE: The application of automated image analyses could improve and facilitate standardization and consistency of quantification in [(18)F]DCFPyL (PSMA) PET/CT scans. In the current study, we analytically validated aPROMISE, a software as a medical device that segments organs in low-dose CT image...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnsson, Kerstin, Brynolfsson, Johan, Sahlstedt, Hannicka, Nickols, Nicholas G., Rettig, Matthew, Probst, Stephan, Morris, Michael J., Bjartell, Anders, Eiber, Mathias, Anand, Aseem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803714/ https://www.ncbi.nlm.nih.gov/pubmed/34463809 http://dx.doi.org/10.1007/s00259-021-05497-8

Ejemplares similares

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia
por: Werner, Rudolf A., et al.
Publicado: (2017)

Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution
por: Ferreira, Gonçalo, et al.
Publicado: (2019)

(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
por: Mesci, Aruz, et al.
Publicado: (2023)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
por: Roy, Jyoti, et al.
Publicado: (2021)

Uptake of [(18)F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies
por: Rowe, Steven P., et al.
Publicado: (2015)

High uptake of (68)Ga-PSMA and (18)F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes
por: Oliveira, Dennis, et al.
Publicado: (2020)

Non-prostate cancer tumours: incidence on (18)F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients
por: Perry, Elisa, et al.
Publicado: (2022)

Cylindroma, an uncommon presentation on (18)F-DCFPyL PET/CT
por: Koene, B. P. F., et al.
Publicado: (2020)

A new automated and putatively versatile synthesis of the PSMA-ligand derivative [(18)F]DCFPyL using the FASTlab(TM) synthesizer
por: Hoareau, Raphaël, et al.
Publicado: (2022)

Threshold for defining PSMA-positivity prior to (177)Lu-PSMA therapy: a comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL in metastatic prostate cancer
por: Heilinger, Jan, et al.
Publicado: (2023)

The Impact of (18)F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

(18)F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center
por: Metser, Ur, et al.
Publicado: (2021)

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
por: Zhou, Shuoming, et al.
Publicado: (2022)

(18)F DCFPyL PSMA avid biopsy proven subcutaneous capillary haemangioma as a malignancy mimic in the setting of biochemical recurrent prostate carcinoma
por: Dhillon, Manvinder, et al.
Publicado: (2022)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

The differential diagnostic value of dual-phase (18)F-DCFPyL PET/CT in prostate carcinoma
por: Tian, Aijuan, et al.
Publicado: (2022)

Short-duration dynamic [(18)F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [(18)F]DCFPyL PET/MR at 120 minutes
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

Intra-patient comparison of physiologic (68)Ga-PSMA-11 and (18)F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay
por: Osman, Medhat M., et al.
Publicado: (2021)

Assessment of (18)F-DCFPyL PSMA PET/CT and PET/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability
por: Lawrence, Edward M., et al.
Publicado: (2023)

Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models
por: Bouvet, Vincent, et al.
Publicado: (2016)

Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020)

Uptake of prostate-specific membrane antigen-targeted (18)F-DCFPyL in avascular necrosis of the femoral head
por: Torga, Gonzalo, et al.
Publicado: (2019)

Uptake of prostate-specific membrane antigen-targeted (18)F-DCFPyL in avascular necrosis of the femoral head
por: Safali, Selim, et al.
Publicado: (2020)

Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
por: Bodar, Y. J. L., et al.
Publicado: (2020)

Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
por: Wondergem, M., et al.
Publicado: (2019)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Pathological predictors of (18)F‐DCFPyL prostate‐specific membrane antigen‐positive recurrence after radical prostatectomy
por: Perry, Elisa, et al.
Publicado: (2022)

Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on (18)F-DCFPyL PET/CT Scans
por: Garg, Tushar, et al.
Publicado: (2022)

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of (18)F-DCFPyL PET/CT Restaging
por: Liu, Wei, et al.
Publicado: (2020)

(18)F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
por: Metser, Ur, et al.
Publicado: (2022)

The diagnostic performance of (18)F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis
por: Pang, Wenyang, et al.
Publicado: (2023)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

PSA-Stratified Performance of [(18)F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy
por: Harsini, Sara, et al.
Publicado: (2022)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis
por: Sun, Jiale, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qh0k6hv4d12anfob2rvacmk2pt